



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of  Paul J. Godowski, et al.  Serial No. 09/480,977  Filed: 11 January 2000  For: ErbB4 RECEPTOR-SPECIFIC NEUREGULIN RELATED LIGANDS AND USES THEREFOR	Group Art Unit: 1642  Examiner: Holleran, Anne L.  Confirmation No: 5001  Customer No: 09157
	<b>EXPRESS MAIL LABEL NO.: EV 351 927 256 US</b> <b>DATE OF DEPOSIT: JANUARY 18, 2005</b>

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**DECLARATION UNDER 37 C.F.R. § 1.131**

I, Paul J. Godowski, Melanie Rose Mark, and Dong Xiao Zhang, declare and say as follows:

CONSIDERED  
PAH  
1/29/05

1. I am a named inventor of the claimed subject matter of the above-identified patent application. The above-identified patent application claims priority to U.S. Patent Application No. 08/899,437, filed July 24, 1997, which claims priority to U.S. Provisional Application No. 60/052,019, filed July 9, 1997. These priority applications name me or one or more of the other named inventors as inventor.
2. All work described in the above-identified application, the priority patent applications, and the sequence information attached as Exhibit A was performed by me or one of the other named inventors, or on our behalf, in the United States of America.
3. I am aware that some of the claims in the above-identified patent application have been rejected as allegedly anticipated by US Patent 6,727,077, which claims priority to U.S. Provisional Application 60/049,492, filed June 17, 1997.
4. Prior to June 17, 1997, I or one or more of the other named inventors, or a person acting on our behalf, reduced to practice in the United States the NRL EGF-like domain, designated the NRG3 EGF-like domain and SEQ ID NO:4 in the present application.